Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
View Patent ↗The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
1. A peptide consisting essentially of the amino acid sequence of SEQ ID NO:16.
2. A pharmaceutical composition in unit dose form comprising a guanylate cyclase receptor agonist peptide having the sequence of SEQ ID NO:16 present in a therapeutically effective amount and a pharmaceutical carrier, excipient or diluent.
3. The pharmaceutical composition of claim 2 , wherein the unit dose form is selected from the group consisting of a tablet, a capsule, a solution and inhalation formulation.
4. A method for treating a condition selected from the group consisting of Ulcerative Colitis, Irritable bowel syndrome (IBS), non-ulcer dyspepsia chronic intestinal pseudo-obstruction, functional dyspepsia, colonic pseudo-obstruction, duodenogastric reflux, constipation associated with use of opiate pain killers, gastroesophageal reflux disease (GERD), post surgical constipation, gastroparesis, constipation associated with neuropathic disorders, heartburn, poor gastrointestinal motility , congestive heart failure, hypertension, bronchitis, tissue inflammation, organ inflammation, respiratory inflammation, asthma, and COPD comprising administering to a patient in need thereof, an effective dosage of a guanylate cyclase receptor agonist having the sequence of SEQ ID NO:16.
5. The method of claim 4 , further comprising administering an effective dose of a cGMP-dependent phosphodiesterase inhibitor.
6. The method of claim 5 , further comprising administering to said patient an effective dose of a cGMP-dependent phosphodiesterase inhibitor either concurrently or sequentially with said guanylate cyclase receptor agonist.
7. The method of claim 6 , wherein said cGMP-dependent phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.
8. The method of claim 5 , further comprising administering an effective does of at least one anti-inflammatory agent.
9. The method of claim 8 , wherein said anti-inflammatory agent is a steroid or nonsteroid anti-inflammatory drug (NSAID).
10. A method of increasing cGMP production in a cell comprising contacting said cell with a peptide comprising the amino acid sequence of SEQ ID NO:16.
11. The method of claim 10 , further comprising contacting said cell with a cGMP-dependent phosphodiesterase inhibitor.
12. The method of claim 11 , wherein said cGMP-dependent phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.